PubMed Health⌕ Search

Biomedical subjects

C Tautz

Publications and source records attributed to C Tautz.

8 recordsLinked to original sources
PubMed1992

A novel HLA-haplotype containing a DRB5 gene not associated with DRB1*15 or DRB1*16 alleles.

In Caucasians, HLA-DR2 haplotypes usually express two DRB genes encoding the DR specificity. The DRB5 genes are in strong linkage disequilibrium with the respective DRB1*15 or DRB1*16 alleles. So far, no other DRB1 alleles have been found in association with DRB5 genes. Here, we report evidence for a probably recombinant DRB5 haplotype with a DRB1 allele not specific for DR2. From our results the haplotype DQB1*0501, DRB1*0101 and DRB5*0101 seems most likely.

Adult↗
PubMed1979

[Electrophoretic mobility test in the early diagnosis of malignant tumors; findings in the prestages of cervical and breast cancers].

A double-blind pilot study of 130 female patients was carried out to determine the feasibility and significance of the EM test in the early diagnosis of carcinoma of the female genital organs and breast. Early stages of cervical carcinoma (carcinoma in situ) as well as fibroid adenoma, mastopathy and breast tumors were tested and compared with the results of their manifest forms. Positive results were recorded in 87.5% of the cases of middle-grade to severe epithelial dysplasia (Papanicolaou III and IV) (n = 10) and in 90% of the cases of carcinoma in situ (n = 16). A positive result in 90% of the cases of carcinoma in situ (n = 16). A positive result in 90% of the cases of genital carcinoma was also recorded. In the case of fibroid adenoma (n = 10) and breast tumor (Prechtel I and II) (n = 16), negative results were recorded in 80.8%, whereas in the manifest forms of carcinoma of the breast a positive result of over 95% was shown. As a result of this pilot study, it can be seen that immunological in vitro screening has clinical significance in the early diagnosis of tumors as well as for confirmation of their manifest forms.

Animals↗
PubMed1975

Cell-mediated immunity in patients with renal adenocarcinoma.

The lymphocytotoxicity test was used to study the existence of immunologically active lymphocyte reactions in patients with renal carcinoma at different stages. In 9 patients with an advanced renal carcioma (stage IV) a low lymphocytotoxicity was found, while the examination of 7 patients with stage I and II renal tumours showed a high value of the lymphocytotoxicity test. The clinical importance of the lymphocytotoxicity test is discussed with special interest in a possible immunotherapy.

Adenocarcinoma↗